Phase 1b Study of Pharmacokinetic Interaction, Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure

Trial Profile

Phase 1b Study of Pharmacokinetic Interaction, Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Cimaglermin alfa (Primary) ; Midazolam
  • Indications Acute coronary syndromes; Heart failure
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 18 Mar 2017 Results (n=2) investigating cases of hepatotoxicity from two phase 1 trials (NCT01944683 and NCT01258387) meeting Hy's Law criteria, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 12 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 21 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top